Nasdaq auph.

Aurinia Pharmaceuticals Inc. (AUPH) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 9.06 +0.42 (+4.86%) At close: 04:00PM EST 8.94 -0.12 (-1.32%) After hours: 07:59PM EST 1dAldeyra Therapeutics Inc (NASDAQ:ALDX) has a beta value of 1.43 and has seen 0.58 million shares traded in the recent trading session. The company, currently valued at $177.64M, closed the recent trade at $3.02 per share which meant it gained $0.16 on the day or 5.59% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and has …This page of Aurinia Pharmaceuticals (AUPH) displays a brief signal update and a market outlook, as well as a candlestick chart showing the last detected ...Based on analysts offering 12 month price targets for AUPH in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

December 4, 2023. Technologies. Vertex Energy Inc (NASDAQ:VTNR) has a beta value of 1.68 and has seen 0.54 million shares traded in the recent trading session. The company, currently valued at $348.79M, closed the recent trade at $3.73 per share which meant it gained $0.11 on the day or 3.04% during that session.Sep 18, 2023 · What happenedAurinia Pharmaceuticals (NASDAQ: AUPH), a company focused on developing treatments for autoimmune diseases, saw its share price fall by more than 5% in early trading on Monday. The ...

Fintel reports that on July 6, 2023, Cantor Fitzgerald reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight recommendation. Analyst Price Forecast Suggests 64.02% UpsideAurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the company announced that its ...

If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...T2 Biosystems, Inc. Common Stock. $0.2229 +0.002. Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US ...Aurinia Pharmaceuticals ( AUPH 3.43%), a small-cap commercial-stage drugmaker, is having another strong session today. Specifically, the biotech's stock was up by 11.9% on moderate volumes as of 1 ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for ...With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a ...

Based on analysts offering 12 month price targets for AUPH in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders Insiders own 2.02% of the company shares, while shares held by institutions stand at 60.74% with a share float percentage of 61.99%. Investors are also buoyed by the number of investors in a company, with Aldeyra Therapeutics Inc having a total of 142 institutions that hold shares in the ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ranks 6th in our list of the best stocks with exponential growth according to hedge funds. In September Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ...View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ. Nov 29, 2023 · The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00. Learn more on AUPH's analyst rating history. Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors? Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.Aurinia Pharmaceuticals ( AUPH 3.43%), a small-cap commercial-stage drugmaker, is having another strong session today. Specifically, the biotech's stock was up by 11.9% on moderate volumes as of 1 ...

Noteworthy Friday Option Activity: W, ON, AUPH. July 28, 2023 — 04:50 pm EDT. Written by BNK Invest for BNK Invest ->. Looking at options trading activity among components of the Russell 3000 ...1 day ago · Nasdaq Auph, also known as Aurinia Pharmaceuticals, is a biopharmaceutical company that focuses on developing and commercializing therapies to treat autoimmune diseases. With a strong pipeline of innovative drugs and a commitment to improving patients’ lives, Nasdaq Auph has garnered attention from investors and industry experts alike. Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include stock option expenses where possible. Nasdaq provides visual representation of analyst expected ...Within the last quarter, Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings: Menu icon A vertical stack of three evenly spaced horizontal lines.NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 ...2 нояб. 2023 г. ... Aurinia Pharmaceuticals (AUPH) reported better-than-expected Q3 2023 financials on Thursday driven by its lupus nephritis therapy Lupkynis.Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is the most popular stock in this table. On the other hand Great Western Bancorp Inc (NYSE: GWB ) is the least popular one with only 13 bullish hedge fund ...

T2 Biosystems, Inc. Common Stock. $0.2229 +0.002. Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US ...

AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis.Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancinNEW YORK, May 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...In trading on Thursday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) crossed above their 200 day moving average of $8.57, changing hands as high as $8.92 per share. Aurinia Pharmaceuticals ...The agency is also expected to rule on Aurinia Pharmaceuticals Inc's (NASDAQ:AUPH) NDA for voclosporin as a treatment option for lupus nephritis, an autoimmune disorder that leads to inflammation ...Nov 20, 2023 · Nov. 20, 2023, 12:38 PM. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the ...

View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Price. 9.06. +4.86%. Webull offers AUPH Ent Holdg (AUPH) historical stock prices, in-depth market analysis, NASDAQ: AUPH real-time stock quote data, in-depth charts, free AUPH options chain data, and a fully built financial calendar to help you invest smart. Buy AUPH stock at Webull.

Dec 4, 2023 · December 4, 2023. Company. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a beta value of 1.39 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $1.27B, closed the recent trade at $8.82 per share which meant it lost -$0.24 on the day or -2.60% during that session. T2 Biosystems, Inc. Common Stock. $0.2229 +0.002. Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US ...The new research reports from Capital Review, available for free download at the links above, examine Adverum Biotechnologies, Inc. (NASDAQ:ADVM), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), Baytex ...At Aurinia, we embrace the possibility to change the trajectory of autoimmune diseases with unmet needs. With a growing pipeline and a dynamic team of proven experts, our work is patient-centric and driven by a sense of urgency. See how we are poised to deliver on our mission. Learn More.Dec 1, 2023 · AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis. Aurinia Pharmaceuticals AUPH rose almost 5.8% on Jun 30, as management announced that it is exploring strategic alternatives for the company’s future. AUPH will consider a range of options ...Fintel reports that on July 6, 2023, Cantor Fitzgerald reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight recommendation. Analyst Price Forecast Suggests 64.02% UpsideNov 27, 2023 · Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ... View Inc. (NASDAQ:VIEW) has a beta value of 0.59 and has seen 11.47 million shares traded in the recent trading session. The company, currently valued at $6.84M, closed the recent trade at $1.68 per share which meant it gained $0.65 on the day or 63.11% during that session. ... Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a …Aurinia Pharmaceuticals ( NASDAQ: AUPH) traded ~5% higher pre-market Thursday after the Canadian biotech increased its full-year guidance and posted better-than-expected financials for Q2 2023 ...ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia welcomes the 2023 updated recommendations from The European ...

9. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Burrage Capital owned just over 362,000 shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) on September 30 and was more bullish on the stock during ...Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ... NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 ...As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.Instagram:https://instagram. ev battery company stockswhich platform allows short sellingbuying stock in tesladoes alcohol affect afib Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical … prop trading firmscan you refinance into a usda loan Dec 4, 2023 · Year-to-date, Rivian Automotive Inc shares have moved -4.45%, while the 5-day performance has seen it change 5.70%. Over the past 30 days, the shares of Rivian Automotive Inc (NASDAQ:RIVN) have changed 0.11%. Short interest in the company has seen 103.62 million shares shorted with days to cover at 2.62. Wall Street analysts have a consensus ... Given this risk, we thought we'd take a look at whether Aurinia Pharmaceuticals (NASDAQ:AUPH) shareholders should be worried about its cash burn. … cathy woods stocks Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its ...Aurinia Pharmaceuticals (NASDAQ:AUPH) is a company that specializes in developing treatments for diseases that currently have few treatment options. They focus on autoimmune, kidney, and rare ...Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the company announced that its ...